haemophilia

Protected: How pharma can boost engagement by embracing support networks

https://pharmaphorum.com/patients/insights-patients/how-pharma-can-boost-engagement-by-embracing-support-networks/

Roche’s Hemlibra approved in expanded haemophilia A use

https://pharmaphorum.com/news/roches-hemlibra-approved-in-expanded-haemophilia-a-use/

Sanofi’s rare disease drug Cablivi approved in the EU

https://pharmaphorum.com/news/sanofi-cablivi-approved-europe/

Roche reveals haemophilia drug data ahead of label expansion decision

https://pharmaphorum.com/news/roche-reveals-hemlibra-drug-data-ahead-expansion-decision/

Pfizer moves haemophilia gene therapy into phase 3

https://pharmaphorum.com/r-d/pfizer-haemophilia-b-gene-therapy/

Europe: thumbs up for Roche’s Hemlibra, Chiesi rare disease drug, bad news for Santhera

https://pharmaphorum.com/news/roches-haemophilia-drug-poised-hit-eu-market/

After losing out on two big deals, Sanofi to buy Bioverativ for $11.6bn

https://pharmaphorum.com/news/losing-two-big-deals-sanofi-buys-bioverativ-11-6bn/

‘Cure for hemophilia within reach’ as BioMarin and Spark gene therapies shine

https://pharmaphorum.com/news/cure-hemophilia-within-reach-biomarin-spark-gene-therapies-shine/

Spark and Pfizer’s gene therapy wows in haemophilia B

https://pharmaphorum.com/news/spark-pfizers-gene-therapy-wows-haemophilia-b/

1 2 3

Close in 10 seconds

Pharmaphorum.com

Search